Analysis of the polymerase gene of HBV virus
| Project/Area Number |
18590725
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Gastroenterology
|
|---|
| Research Institution | University of Yamanashi |
|---|
Principal Investigator |
KUROSAKI Masayuki University of Yamanashi, Deparment of Research Interdisciplinary, Graduate School of Medicine and Engineering, Research Fellow (10280976)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
IZUMI Namiki University of Yamanashi, Deparment of Research Interdisciplinary, Graduate School of Medicine and Engineering, Research Fellow (20397300)
ENOMOTO Nobuyuki University of Yamanashi, Deparment of Research Interdisciplinary, Graduate School of Medicine and Engineering, Professor (20251530)
|
|---|
| Project Period (FY) |
2006 – 2007
|
| Project Status |
Completed (Fiscal Year 2007)
|
| Budget Amount *help |
¥4,010,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥510,000)
Fiscal Year 2007: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Fiscal Year 2006: ¥1,800,000 (Direct Cost: ¥1,800,000)
|
|---|
| Keywords | Henatitis B virus / Polymerase gene / mutation / Lamivudine / breakthrough hepatitis / Polymerase遺伝子 / domain B / domain A / polymerase遺伝子 |
|---|
| Research Abstract |
The mutational pattern of the polymerase gene in HBV carriers under lamivudine (LAM) treatment was examined. Mutation in the rt204 of the polymerase gene (so called YMDD motif) was detected in 28% of patients with persistently negative for HBVDNA. These latent mutations without clinically obvious breakthrough, progressed to overt viral breakthrough in 80% of patients within 2 years of LAM treatment, 33% of patients with 3 to 5 years of LAM treatment and 0% of patients with 5 or more years of LAM treatment In addition some patients had mutation in the rt180, which was positively correlated with subsequent development of viral breakthrough. Mutations in rt80 was also frequently observed but was not related to clinical outcomes.
In the analysis of patients with long term entecavir therapy for LAM resistant virus, those without clearance of HBV at week 24 had higher risk of developing resistant virus. The rt204V mutation may be related to higher risk of resistance, which need further investigations.
|
Report
(3 results)
Research Products
(15 results)
-
-
-
[Journal Article] The presence of steatosis and elevation of alanine aminotransferase level are associated with fibrosis progression in chronic hepatitis C with non-response to interferon therapy2008
Author(s)
Kurosaki, M., Matsunaga, K., Hirayama, I., Tanaka, T., Sato, M., Komatsu, N., Umeda, N., Hosokawa, T., Ueda, K., Tsuchiya, K., Nakanishi, H., Itakura, J., Asahina, Y., Miyake, S., Enomoto, N., Izumi, N
-
Journal Title
Journal of Hepatology 48
Pages: 736-736
Description
「研究成果報告書概要(欧文)」より
Related Report
-
-
-
-
-
-
-
-
-
-
-
-
